share_log

424B2: Prospectus

SEC announcement ·  Apr 25 15:52
Summary by Moomoo AI
JPMorgan Chase Financial Company LLC, a subsidiary of JPMorgan Chase & Co., has launched a new structured investment product linked to Tesla, Inc.'s stock. The $2 million Auto Callable Contingent Interest Notes, priced on April 23, 2024, are due on October 28, 2025, and are designed to pay contingent interest based on the performance of Tesla's stock. The notes will be automatically called if Tesla's stock price on any Review Date, excluding the first, second, and final Review Dates, meets or exceeds its Initial Value. The first possible automatic call date is set for July 23, 2024. These unsecured and unsubordinated obligations carry risks, including the potential loss of principal and the possibility of receiving no interest payments. The notes, guaranteed by JPMorgan Chase & Co., were settled on or about April 26, 2024, with a minimum investment of $1,000. The offering includes risks detailed in the prospectus supplement and the product supplement, and the SEC has not approved or disapproved the notes nor passed upon the accuracy of the supplements.
JPMorgan Chase Financial Company LLC, a subsidiary of JPMorgan Chase & Co., has launched a new structured investment product linked to Tesla, Inc.'s stock. The $2 million Auto Callable Contingent Interest Notes, priced on April 23, 2024, are due on October 28, 2025, and are designed to pay contingent interest based on the performance of Tesla's stock. The notes will be automatically called if Tesla's stock price on any Review Date, excluding the first, second, and final Review Dates, meets or exceeds its Initial Value. The first possible automatic call date is set for July 23, 2024. These unsecured and unsubordinated obligations carry risks, including the potential loss of principal and the possibility of receiving no interest payments. The notes, guaranteed by JPMorgan Chase & Co., were settled on or about April 26, 2024, with a minimum investment of $1,000. The offering includes risks detailed in the prospectus supplement and the product supplement, and the SEC has not approved or disapproved the notes nor passed upon the accuracy of the supplements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more